Abstract 103 Table 1b Predictors for transitions to the resolved NP State

SLE NP events		
(n = 270 transitions)		
Variable	HR (CI)	p-value
Asian race/ethnicity*	1.72 (1.17,2.54)	0.006
Any Peripheral	0.89 (0.65,1.24)	0.500
Any Central-Focal	1.74 (1.33,2.27)	<0.001
All Central-Diffuse	1.00	
Past non-SLE NP events (without headache)	0.93 (0.59,1.47)	0.76
Concurrent non-SLE NP events (without headache)	0.63 (0.44,0.91)	0.12
Previous headache	0.98 (0.67,1.43)	0.93
Current headache	0.80 (0.58,1.09)	0.15
Non-SLE NP events excluding headaches		
(n = 176 transitions)		
Variable	HR (CI)	p-value
Hispanic race/ethnicity*	1.43 (0.96,2.13)	0.082
Non-US African race/ethnicity*	2.06 (1.14,3.73)	0.017
Age at SLE diagnosis	0.98 (0.96,0.99)	<0.001
Any Peripheral	0.76 (0.44,1.29)	0.306
Any Central-Focal	1.38 (0.72,2.64)	0.328
All Central-Diffuse	1.00	

*Other race/ethnicities were included in the analysis but the results were not significant.

association with Asian race/ethnicity, post-secondary education, and immunosuppressive or anti-malarial drugs. For non-SLE NP events, excluding headache, there was a positive association with concurrent SLE NP events and negative associations with African and Asian race/ethnicity. NP events attributed to SLE had a higher resolution rate than non-SLE NP events, with the exception of headache that had comparable resolution rates. For SLE NP events, multivariate analysis revealed resolution was more common with Asian race/ethnicity and for central/focal NP events (table 1b). For non-SLE NP events resolution was more common with African race/ethnicity and less common with older age at SLE diagnosis (table 1b).

Model 1 includes time invariant variables or those defined at all time points. Model 2 is restricted to transitions for which there is information as in model 1 and additional time variable explanatory variables available only for events occurring after the initial patient assessment.

Conclusions In a large and long-term study of the occurrence and resolution of NP events in SLE we identified subgroups with better and worse prognosis. The course of NP events differs greatly depending on their nature and attribution.

Acknowledgement This work was completed by members of the Systemic Lupus International Collaborating Clinics (SLICC).

104 DISTINCT SPATIAL PROFILE OF INFLAMMATORY GENE EXPRESSION IN THE BRAIN OF A MOUSE MODEL OF NEUROPSYCHIATRIC LUPUS

^{1,2}Ernest Aw, ¹Yingying Zhang, ^{1,2}Michael C Carroll*. ¹Boston Children's Hospital; ²Program in Immunology, Harvard University

10.1136/lupus-2021-lupus21century.4

Background SLE is an incurable autoimmune disease that results in central nervous system (CNS) involvement with clinical manifestations including anxiety and depression. However, the mechanism/s underlying these neuropsychiatric symptoms

(NPSLE) remain unknown. An elevated type 1 interferon (IFN α) signature has been commonly observed in SLE patients, particularly within the CNS of NPSLE patients (Crow et al., 2014, Shiozawa et al., 1992). Given the diversity of clinical CNS manifestations, we hypothesized that type 1 interferon-mediated inflammation occurs in spatially distinct regions within the CNS, resulting in differential behavioral outcomes depending on the impacted brain region.

Methods Spatial distribution of inflammatory gene expression in the brain was performed using MERFISH, a multiplexed spatial transcriptomics platform employing a custom set of RNA probes. Cell source and *in situ* results were validated by RT-PCR, RNA scope and single nucleus sequencing of RNA (sNuc-Seq).

Results Characterization of *Sle 1*, *yaa* mice in behavior assays, identified anxiety-like, and fatigue-like behaviors consistent with NPSLE. Notably, the behavior changes correlate with distinct patches of interferon stimulated gene (ISG) expression within the subcortical regions of mouse brains. Preliminary single nucleus sequencing (sNuc-Seq) and *in situ* hybridization results implicate astrocytes and oligodendrocytes as the major cell classes enriched in these ISG patches.

Conclusions In summary, our results validate a mouse behavioral model of NPSLE, and show spatially distinct regions of ISG expression within the CNS, opening up a new avenue of investigation into the fundamental mechanisms of NPSLE.

Acknowledgements The work was supported by a grant from the NIH R01AR072965.

200 – Cutaneous SLE

201 TYPE I INTERFERON MODULATES LANGERHANS CELL ADAM17 IN LUPUS TO CONTRIBUTE TO PHOTOSENSITIVITY

¹Thomas M Li, ^{1,2}Keila R Veiga, ^{1,3}Noa Schwartz, ^{4,5}Jose Lora, ⁶Ali Jabbari, ⁷Yong Liu, ^{1,8}William D Shipman, ^{1,9}Marvin J Sandoval, ¹Isabel F Sollohub, ¹⁰Mehdi Rashighi, ⁶James G Krueger, ⁷Niroshana Anandasabapathy, ¹¹David J Oliver, ¹¹Yurii Chinenov, ^{4,5}Carl P Blobel, ^{1,2,3,9}Theresa T Lu*. ¹Autoimmunity and Inflammation Program, HSS Research Institute, New York, NY 10021, USA; ²Pediatric Rheumatology, Department of Medicine, Hospital for Special Surgery, New York, NY, USA; ³Rheumatology, Department of Medicine, Hospital for Special Surgery, New York, NY USA; ⁴Arthritis and Tissue Degeneration Program, HSS Research Institute, New York, NY, USA; ⁵Department of Physiology, Biophysics, and Systems Biology, Weill Cornell Medicine, New York, NY, USA; ⁶Laboratory of Investigative Dermatology, Rockefeller University, New York, NY, USA; ⁷Department of Dermatology, Weill Cornell Medical College, New York, NY, USA; ⁸Weill Cornell Tri-Institutional MD-PhD Program, New York, NY, USA; ⁹Department of Microbiology and Immunology, Weill Cornell Medicine, New York, NY, USA; ¹⁰Department of Dermatology, University of Massachusetts Medical School, Worcester, MA, USA; ¹¹David Z. Rosensweig Genomics Research Center, HSS Research Institute, New York, NY, USA

10.1136/lupus-2021-lupus21century.5

Background Photosensitivity is a common feature in systemic lupus erythematosus (SLE), is considered to be a major contributor to SLE skin disease, and can be associated with serious flares of systemic disease, but mechanistic understanding remains limited. Several lines of evidence including the finding of a type I interferon (IFN-I) signature in non-lesional skin, the potentiation of keratinocyte apoptosis by IFN-I, the importance of IFNAR in murine lupus model skin lesion development, and the improved skin scores in the clinical trials of anifrolumab (anti-IFNAR1) point to a pathogenic role for IFN-I in SLE skin disease. We recently showed that Langerhans cells (LCs) limit UVR-induced keratinocyte apoptosis and skin injury via ADAM17-mediated EGFR ligand activation and